Claims for Patent: 6,818,405

Summary for Patent: 6,818,405

Title:	Therapeutic use of the SMR1 protein and active derivatives thereof
Abstract:	The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting ligand molecules that possess an agonist or an antagonist\' biological activity on the target receptor of the QHNPR pentapeptide as well as to the selected ligand molecules themselves.
Inventor(s):	Rougeot; Catherine (Chevreu, FR), Rougeon; Francois (Sevres, FR)
Assignee:	Institut Pasteur (Paris, FR)
Application Number:	09/367,703
Patent Claims:	1. A method for treating a disease caused by a mineral imbalance, comprising administering to a mammal a pharmaceutically active amount of: (A) an SMR1 protein comprising SEQ ID NO:14, (B) a fragment of the SMR1 protein comprising SEQ ID NO:14, (C) a maturation product of the SMR1 protein comprising SEQ ID NO:1, SEQ ID NO:7 or SEQ ID NO:12, or (D) a derivative of the SMR1 protein of(A), the fragment of(B) or the maturation product of (C) that comprises at least one modified amino acid residue, which has improved stability and which retains the mineral imbalance modulating activity of the protein of (A), the fragment of (B) or the maturation product of (C), and wherein said protein, fragment, maturation product or derivative modulates mineral ion concentration. 2. The method of claim 1, wherein said mammal is a human. 3. The method of claim 1, comprising administering a peptide consisting of formula XQHNPR (SEQ ID NO: 14). 4. The method of claim 1, comprising administering a peptide consisting of QHNPR (SEQ ID NO: 1). 5. The method of claim 1, comprising administering a peptide consisting of VQHNPR (SEQ ID NO: 2). 6. The method of claim 1, comprising administering a peptide consisting of VRQHNPR (SEQ ID NO: 3). 7. The method of claim 1, comprising administering a peptide consisting of VRGQHNPR (SEQ ID NO: 4). 8. The method of claim 1, administering a peptide consisting of VRGPQHNPR (SEQ ID NO: 5). 9. The method of claim 1, comprising administering a peptide consisting of VRGPRQHNPR (SEQ ID NO: 6). 10. The method of claim 1, comprising administering a peptide consisting of VRGPRROHNPR (SEQ ID NO: 7). 11. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative comprises one or more amino acid(s) in the D-form. 12. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative is administered in a liquid solution. 13. The method of claim 1, said SMR1 protein, fragment, maturation product or derivative is administered in a gel. 14. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative is administered as a dry powder. 15. The method of claim 1, said SMR1 protein, fragment, maturation product or derivative is administered via a controlled drug delivery device. 16. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative is administered locally near a site to be treated. 17. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative is administered orally. 18. The method of claim 1, comprising administering an SMR1 protein comprising SEQ ID NO: 14. 19. The method of claim 1, comprising administering a fragment of an SMR1 protein, wherein said SMR1 protein comprises SEQ ID NO: 14. 20. The method of claim 1, comprising administering a maturation product of an SMR1 protein, wherein said SMR1 protein comprises SEQ ID NO: 14. 21. The method of claim 1, comprising administering a derivative. of an SMR1 protein, wherein said SMR1 protein comprises SEQ ID NO: 14. 22. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative is administered in the form of a pharmaceutical composition. 23. The method of claim 22, wherein said pharmaceutical composition further comprises one or more of parathyroid hormone (PTH), calcitonin (CT) or 1,25-dihydroxyvitamin D. 24. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative is administered in a dose ranging from 10 .mu.g/kg to 10 mg/kg of body weight. 25. The method of claim 1, wherein said SMR1 protein, fragment, maturation product or derivative is administered in a dose ranging from 200 .mu.g/kg to 1 mg/kg of body weight. 26. A method for treating a disorder affecting the bone in a mammal, comprising administering to the mammal a pharmaceutically active amount of: (A) an SMR1 protein comprising SEQ ID NO: 14, (B) a fragment of the SMR1 protein comprising SEQ ID NO: 14, (C) a maturation product of the SMR1 protein comprising SEQ ID NO:1, SEQ ID NO:7 or SEQ ID NO:12, or (D) a derivative of the SMR1 protein of(A), the fragment of(B) or the maturation product of (C) that comprises at least one modified amino acid residue, which has improved stability and which retains the mineral imbalance modulating activity of the protein of (A), the fragment of (B) or the maturation product of (C), and wherein said protein, fragment, maturation product or derivative modulates mineral ion concentration. 27. The method of claim 26, comprising treating a mammal having osteoporosis. 28. The method of claim 26, wherein said mammal is a human. 29. The method of claim 29, administering a peptide consisting of formula XQHNPR (SEQ ID NO: 14). 30. The method of claim 26, comprising administering a peptide consisting of QHNPR (SEQ ID NO: 1). 31. The method of claim 26, comprising administering a peptide consisting of VQHNPR (SEQ ID NO: 2). 32. The method of claim 26, comprising administering a peptide consisting of VRQHNPR (SEQ ID NO: 3). 33. The method of claim 26, administering a peptide consisting of VRQHNPR (SEQ ID NO: 4). 34. The method of claim 26, comprising administering a peptide consisting of VRGPQHNPR (SEQ ID NO: 5). 35. The method of claim 26, comprising administering a peptide consisting of VRGPRQHNPR (SEQ ID NO: 6). 36. The method of claim 26, comprising administering a peptide consisting of VRGPRRQHNPR (SEQ ID NO: 7). 37. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative comprises one or more amino acid(s) in the D-form. 38. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered in a liquid solution. 39. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered in a gel. 40. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered as a dry powder. 41. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered via a controlled drug delivery device. 42. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered locally near a site to be treated. 43. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered orally. 44. The method of claim 26, administering an SMR1 protein comprising SE NO: 14. 45. The method of claim 26, comprising administering a fragment of SMR1 protein, wherein said SMR1 protein comprises SEQ ID NO: 14. 46. The method of claim 26, comprising administering a maturation product of an SMR1 protein, wherein said SMR1 protein comprises SEQ ID NO: 14. 47. The method of claim 26, comprising administering a derivative of an SMR1 protein, wherein said SMR1 protein comprises SEQ ID NO: 14. 48. The method of claim 26, said SMR1 protein, fragment, maturation product or derivative is administered in the form of a pharmaceutical composition. 49. The method of claim 48, wherein said pharmaceutical composition further comprises one or more of parathyroid hormone (PTH), calcitonin (CT) or 1,25-dihydroxyvitamin D. 50. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered in a dose ranging from 10 .mu.g/kg to 10 mg/kg of body weight. 51. The method of claim 26, wherein said SMR1 protein, fragment, maturation product or derivative is administered in a dose ranging from 200 .mu.g/kg to 1 mg/kg of body weight. 52. A method for determining the amount of SMR1 protein, fragment, maturation product or derivative thereof to be administered to a patient suffering from a metabolic imbalance or a mineral ion imbalance, wherein (A) the SMR1 protein comprises SEQ ID NO:14, (B) the fragment of the SMR1 protein comprises SEQ ID NO:14, (C) the maturation product of the SMR1 protein comprises SEQ ID NO:1, SEQ ID NO:7 or SEQ ID NO:12, and (D) the derivative of the SMR1 protein of (A), the fragment of (B) or the maturation product of (C) has at least one modified amino acid residue for improved stability and which retains the mineral imbalance modulating activity of the protein of (A), the fragment of (B) or the maturation product of (C), and wherein said protein, fragment, maturation product or derivative modulates mineral ion concentration, the method comprising: a) incubating a labeled peptide comprising XQHNPR (SEQ ID NO:14) with a polyclonal or a monoclonal antibody directed against the peptide to form an immune complex; b) contacting said immune complex with a biological sample from a patient to be tested, wherein said sample is suspected to contain an endogenous non-labeled peptide comprising XQHNPR (SEQ ID NO:14); c) detecting the amount of monoclonal or polyclonal antibody-bound labeled peptides that have not been displaced by the non-labeled endogenous peptide comprising XQHNPR (SEQ ID NO:14) contained in the biological sample, thus determining the concentration of the endogenous peptide in the sample; d) comparing the concentration of the peptide comprising XQHNPR (SEQ ID NO:14) in the biological sample from the patient with the concentration of the peptide comprising XQHNPR (SEQ ID NO:14) normally found in a healthy individual; and e) calculating the amount of SMR1 protein, fragment, maturation product or derivative necessary to supply the defect in the SMR1 protein or maturation factor in body fluids or tissues of said patient. 53. The method of claim 52, that comprises determining the amount of the peptide QHNPR (SEQ ID NO: 1) to be administered to a patient. 54. The method of claim 52, wherein said sample is plasma. 55. The method of claim 52, wherein said sample is urine. 56. The method of claim 52, wherein said sample is saliva. 57. The method of claim 52, wherein said labeled peptide is labeled QHNPR (SEQ ID NO: 1) peptide.

Details for Patent 6,818,405

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26